Detorubicin (hydrochloride)

Detorubicin hydrochloride (NSC 292652 hydrochloride) is a semi-synthetic analog of Daunorubicin (HY-13062A) and a prodrug of Doxorubicin (HY-15142A). Detorubicin hydrochloride hydrolyzes to release Doxorubicin under neutral pH conditions. Detorubicin hydrochloride forms complexes with DNA. Detorubicin hydrochloride exhibits anti-hematologic tumor and metastatic melanoma activities. Detorubicin hydrochloride causes myocardial injury, skin damage, alopecia, and high mortality in golden hamsters. Detorubicin hydrochloride can be used in research related to leukemia, and metastatic melanoma^[1][2][3][4]. In Vitro:Detorubicin (20-120 min) shows pH-dependent stability in cell-free solutions, with the highest stability at pH 4.5 (half-life 600 min), intermediate stability at pH 6.5 (half-life 24 min), and lowest stability at pH 7.4 (half-life 4.6 min)^[1]. In Vivo:Detorubicin hydrochloride shows greater potency than doxorubicin against subcutaneously inoculated L1210 murine leukemia^[1].
Detorubicin (3 mg/kg; i.p.; three times a week; up to 4 weeks) hydrochloride causes 100% mortality in golden hamsters, alongside severe myocardial ultrastructural damage and degenerative skin lesions with alopecia^[4].